Michael F. Mahoney Joins Baxter’s Board of Directors
“Mike’s significant knowledge of the global medical products business and his track record of leadership will make a significant contribution to Baxter’s Board.” These were the encouraging words of Chairman Robert L. Parkinson, Jr., when welcoming Michael F. Mahoney to Baxter’s Board of Directors.
Mahoney, who has both a Bachelor’s degree in Finance and Masters in Business Administration, has also been the CEO and President of Boston Scientific Corporation since 2012. Previously he served as Group Chairman at DePuy and Worldwide Chairman for the Medical Devices and Diagnostic group at Johnson & Johnson. Mahoney is equally pleased to join the board noting that Baxter provides a solid foundation for growth. He will lend his skills to the governance and compensation committee.
Helius Medical Technologies Names Joyce LaViscount CFO/COO
After several months serving on Helius Medical Technologies Inc.’s Board of Directors, Joyce LaViscount is now the CFO/COO following the resignation of former CFO, Amanda Tseng. Prior to her new position, she also served as CPO/COO at MediMedia Health. She brings more than 28 years of pharmaceutical experience in finance and operations. Her talents have helped to improve the performances of many companies including Pfizer and Bristol-Myers Squibb.
CEO Philippe Deschamps looks forward to the positive changes LaViscount will bring to the company, noting, “Her passion, enthusiasm and expertise for the proper financial and operation systems will continue to drive shareholder value as we prepare to commercialize our PoNS Technology.”
Announced Scott Cooper as the company’s new Chief Financial Officer and Vice President of Business Development. He has a reputable record, with more than 25 years experience in financial operations and accounting. He served as CFO of WaveTec Vision Systems Inc. since 2007 and recently led the sale of WaveTec to Alcon, a division of Novartis.
Appointed Adele Sommerfeld as Chief Executive Officer. Sommerfeld brings more than 25 years of experience in the biotech industry with expertise in equity financing, corporate strategy, strategic partnering and business development. AVAX looks forward to the enhancement of their management team with Sommerfeld’s appointment as they continue to work towards cancer vaccine development.
Announced that Adi Mohanty, who has been serving the company as Chief Operating Officer since 2014, will now partner with Michael D. West, PhD as Co-CEO. Mohanty will be responsible for science technology development and intellectual property activities. Since 2014, Mohanty has led the company to numerous operational and strategic achievements.
CANbridge Life Sciences
Named Dr. Mark A. Goldberg as Chief Medical Officer. Dr. Goldberg previously served as Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation. Dr. Goldberg has accumulated 30 years of practice in clinical and industry experience, as an oncologist, hematologist and corporate medical regulatory strategist.
Appointed Glenn P. Muir, CPA to its Board of Directors. Muir brings more than 30 years of financial experience, most recently as Executive VP and CFO of Hologic, Inc. There, he helped transform the niche company into a multi-dimensional diagnostic imaging systems leader—something G1 aims for as they grow from clinical development to a world-class therapeutics company.
A molecular diagnostic company focused on sepsis patients appointed Dr. Roy F. J. Davis as its new Chief Medical Officer. Dr. Davis brings more than 30 years of experience, most recently serving as Chief Medical Officer at Providence Health and Services’ Alaska region. Dr. Davis gained experience with sepsis surveillance algorithms, which he will implement as Immunexpress advances their molecular diagnostic test for sepsis.
Expanded into the Cambridge biotech field under the new leadership of Megan Thomas, Senior Vice President, Health Practice. Thomas brings more than 20 years of experience to the position, both in corporate leadership and communications.
Announced Dr. Magnus Hansson as Chief Medical Officer. As of January 2016, Dr. Hansson will be in charge of leading clinical research and development activities. His first task will be to bring NeuroVive into the lead of the mitochondrial medicine study.
Promoted James S. Scibetta to President. Scibetta has been serving in the company since 2008 as Chief Finance Officer and in 2014, was appointed to Senior Vice President. His experience adds up to 25 years of financial executive and investment banking, serving public and private healthcare and life science companies.
A company that develops therapies to treat gastrointestinal disease asked Dr. William J. Sandborn to join their Medical Advisory Board. The doctor is currently Chief, Division of Gastroenterology and Director at University of California San Diego Inflammatory Bowel Disease Center and a dedicated Professor of Clinical Medicine. He will lead further developments at Ritter in clinical development and pharmacology.
Welcomed Marsha H. Fanucci on to its Board of Directors. Fanucci has 25 years of experience in the biopharmaceutical financial management and strategic business operations. In 2008 Fanucci played a vital role in Takeda Pharmaceuticals earnings of $8.8 billion. She also achieved multiple profitable gains while serving in several executive leadership roles at Millennium Pharmaceuticals.
Appointed Alan Rosling to its Board Of Directors. He is currently a Senior Advisor at Navam Capital and also became Co-founder of Kiran Energy in 2010. During earlier years Rosling worked as Special Advisor to British Prime Minister John Major, as well as the Executive Director of Tata Sons Limited and as the Chairman of the Jardine Matheson Group.